AttendMe Owl Logo
AttendMe
Evidence Evolution
PulmonologyPulmonology

How This Evidence Evolved

COPD Inhaler Strategy

From LAMA monotherapy through dual bronchodilation to eosinophil-guided triple therapy

18.2

Timeline

TORCH
2007
UPLIFT
2008
INSPIRE
2008
SPARK
2013
FLAME
2016
IMPACT
2018
ETHOS
2020
IMPACT mortality analysis
2020
BOREAS
2023
ENHANCE-1/2
2023
GOLD 2023 Executive Summary
2023
GOLD executive summary
2023
GOLD 2023 guidelines review
2024
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

UPLIFT randomized 5,993 patients with COPD to tiotropium or placebo for four years. Tiotropium improved lung function, quality of life and exacerbation outcomes but did not significantly reduce the rate of FEV1 decline. TORCH compared salmeterol–fluticasone with placebo and either component over three years. Combination therapy reduced annual exacerbations from 1.13 to 0.85 but did not meet the prespecified significance threshold for all-cause mortality (HR 0.825, 95% CI 0.681–1.002; P=0.052). Pneumonia was reported more often with fluticasone-containing treatment: 19.6% with combination therapy versus 12.3% with placebo.
Proof

Landmark RCTs and pivotal trials that established the evidence base

FLAME studied COPD with prior exacerbation. Over 52 weeks, indacaterol-glycopyrronium versus salmeterol-fluticasone yielded all-exacerbation rates of 3.59 versus 4.03/year (rate ratio 0.89, 95% CI 0.83–0.96; P=.003); pneumonia was 3.2% versus 4.8% (P=.02). Effects were independent of baseline blood eosinophils. SPARK: annual moderate/severe exacerbation rates of 0.84 versus 0.95 with indacaterol-glycopyrronium versus glycopyrronium (rate ratio 0.88, 95% CI 0.77–0.99). INSPIRE found no significant annual exacerbation difference with salmeterol-fluticasone versus tiotropium (1.28 vs 1.32; P=.656), with more pneumonia on salmeterol-fluticasone.
Extension

Follow-up studies, subgroup analyses, and real-world validation

IMPACT studied 10,355 patients over 52 weeks. Fluticasone furoate/umeclidinium/vilanterol reduced moderate or severe exacerbations by 15% versus fluticasone furoate/vilanterol and 25% versus umeclidinium/vilanterol. Pneumonia risk was higher than with umeclidinium/vilanterol (HR 1.53, 95% CI 1.22–1.92). ETHOS analyzed 8,509 patients: annual exacerbation rates were 1.08 with higher-dose budesonide triple therapy, 1.42 with glycopyrrolate/formoterol and 1.24 with budesonide/formoterol. The higher-dose triple regimen reduced rates by 24% and 13%, respectively. These regimens improve exacerbation outcomes but require attention to pneumonia risk.
Guidelines

Integration into clinical practice guidelines and recommendations

GOLD 2023 recommends LABA/LAMA initially for groups B and E, with initial triple therapy considered in group E when eosinophils are ≥300 cells/µL. For persistent exacerbations on LABA/LAMA, it recommends escalation to triple therapy at eosinophils ≥100 cells/µL. ICS withdrawal can be considered for pneumonia or substantial side effects; withdrawal at eosinophils ≥300 cells/µL is more likely to lead to exacerbations. Eosinophil count informs expected ICS benefit alongside symptoms and exacerbation history.
GOLD 2023 Executive Summary

Persistent exacerbations on LABA/LAMA: add ICS at eos ≥100 cells/µL. Consider withdrawal for pneumonia/major side effects; eos ≥300 raises withdrawal exacerbation risk.

Now

Current standard of care and ongoing research directions

BOREAS randomized 939 patients with COPD, eosinophils ≥300 cells/µL and exacerbation risk despite standard triple therapy. Dupilumab reduced annualized moderate/severe exacerbations to 0.78 versus 1.10 with placebo (rate ratio 0.70; 95% CI 0.58–0.86). ENHANCE-1 and ENHANCE-2 tested ensifentrine, a dual PDE3/PDE4 inhibitor with bronchodilator and anti-inflammatory effects. Both trials improved lung function; symptom and quality-of-life improvements at week 24 were significant in ENHANCE-1 but not ENHANCE-2. These trials extend evidence beyond inhaled triple therapy while retaining specific populations, comparators and outcome limits.

Landmark Trials in This Story

UPLIFT2008Landmark

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

Rate of decline in FEV1

New England journal of medicineRCTN=5,993
TORCH2007Landmark

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

All-cause mortality

New England journal of medicineRCTN=6,112
FLAME2016Landmark

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD

Rate of all COPD exacerbations

New England journal of medicineRCT
SPARK2013

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

Moderate/severe annual COPD exacerbations: indacaterol-glycopyrronium 0.84 vs glycopyrronium 0.95 (rate ratio 0.88, 95% CI 0.77-0.99, P=0.038)

Lancet Respir MedRandomized parallel-group trial over 64 weeks; QVA149 and glycopyrronium double-blind, tiotropium open-labelN=2,224
INSPIRE2008

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

Annual health-care-utilization exacerbation rate: salmeterol-fluticasone 1.28 vs tiotropium 1.32 (rate ratio 0.967, 95% CI 0.836-1.119, P=0.656)

Am J Respir Crit Care MedRandomized double-blind double-dummy parallel trial over 2 years in severe or very severe COPDN=1,323
IMPACT2018

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Annual rate of moderate or severe COPD exacerbations

The New England journal of medicineRandomized controlled trialN=10,355
ETHOS2020Landmark

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Annual rate of moderate or severe exacerbations

New England journal of medicineRCTN=8,509
IMPACT mortality analysis2020

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.

All-cause mortality: FF/UMEC/VI vs UMEC/VI HR 0.72 (95% CI 0.53–0.99; p=0.042)

American journal of respiratory and critical care medicineSecondary analysis with post hoc vital-status collectionN=10,355
BOREAS2023

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

Annualized moderate/severe COPD exacerbations: dupilumab 0.78 vs placebo 1.10 (rate ratio 0.70; 95% CI 0.58–0.86; p<0.001).

The New England journal of medicinePhase 3 randomized double-blind placebo-controlled trialN=939
ENHANCE-1/22023

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).

Average FEV1 AUC 0–12 h difference vs placebo: ENHANCE-1 +87 mL (95% CI 55–119); ENHANCE-2 +94 mL (65–124); both p<0.001.

American journal of respiratory and critical care medicineTwo phase 3 randomized double-blind placebo-controlled trials

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

When should ICS be added in COPD?+
GOLD 2023 recommends escalation from LABA/LAMA to triple therapy for persistent exacerbations when blood eosinophils are at least 100 cells/µL. Counts at least 300 cells/µL indicate a strong likelihood of ICS benefit; below 100, adding ICS has little or no effect. ICS de-escalation can be considered for pneumonia or other substantial side effects, with greater exacerbation risk after withdrawal when eosinophils are at least 300 cells/µL.
What is the mortality benefit of triple therapy in COPD?+
An updated IMPACT mortality analysis found a death hazard ratio of 0.72 for triple therapy versus umeclidinium/vilanterol (95% CI 0.53–0.99; P=0.042). The comparison with fluticasone/vilanterol was not significant (HR 0.89, 95% CI 0.67–1.16). Time to mortality was prespecified, but additional vital-status collection and these analyses were post hoc.
Is ICS-containing therapy harmful in COPD?+
Pneumonia risk is important. IMPACT found higher clinician-diagnosed pneumonia risk with triple therapy than umeclidinium/vilanterol (HR 1.53, 95% CI 1.22–1.92). In ETHOS, confirmed pneumonia occurred in 3.5–4.5% of ICS-containing groups versus 2.3% with glycopyrrolate/formoterol. GOLD uses exacerbation history and blood eosinophils to guide ICS treatment.
How does the GOLD ABE assessment group guide initial therapy?+
GOLD 2023 uses groups A, B and E. Group A is managed with a bronchodilator. Group B starts LABA/LAMA. Group E also starts LABA/LAMA, with initial triple therapy considered when eosinophils are at least 300 cells/µL. This initial-treatment decision differs from follow-up escalation for persistent exacerbations on dual therapy.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026